Protein

VelosBio Tacks on $137M to Advance Its ROR1-Targeting Cancer Antibody Drugs

1 month ago   |   By Xconomy

Dave Johnson has known UC San Diego physician and cancer reseacher Thomas Kipps for nearly 20 years. Now Johnson, CEO of San Diego-based cancer drug developer VelosBio, has secured $137 million to accelerate the company's goal of developing targeted therapies based on an antibody program developed by Kipps that homes in on tumors with a specific genetic signature. Johnson said it was Kipps' work, which identified ROR1 as a promising cancer protein to target and developed a drug candidate that appeared to find cancer cells that expressed it without harming healthy cells, that “compelled”...
Read more ...

 


Search by Tags

   Protein      Therapies      Cancer      Drug      Drugs      Genetics      National blog main      San Diego      San Diego blog main      San Diego top stories      San Francisco blog main      Seattle blog main      AbbVie      Acerta Pharma      Adage Capital Management      Antibody Drugs      Antibody-drug conjugate      Arix      Arix Bioscience      AstraZeneca      Biotech      Bispecific Antibodies      Calistoga Pharmaceuticals      Cancer      Citadel      Clayton Knox      Clinical trials      Cormorant Asset Management      Dave Johnson      Decheng Capital      Farallon      Financing      Foresite Capital      Funding      Funds and accounts advised by T. Rowe Price Associates      Gilead Sciences      Janus Henderson Investors      JLabs      Johnson & Johnson      Langdon Miller      Life Sciences      Logos Capital      Matrix Capital Management      Mavupharma      Orbimed      Pappas Capital      ROR1      Sofinnova      Sofinnova Ventures      Startups      Surveyor Capital      Takeda      Thomas Kipps      Tom Kipps      UC San Diego      UCSD      VelosBio      Venrock Healthcare Capital Partners      Venture Capital      Viking Global Investors      Wellington Management Company  


World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

2nd International Conference on Tissue Science and Regenerative Medicine

This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...

How COVID-19 Arose and Amplified Along the Meat Supply Chain

How COVID-19 Arose and Amplified Along the Meat Supply Chain

Early in this unforgettable year, a wet market in Wuhan, China, emerged as a possible step along the way, if not the place of origin, of the outbreak that would seed the... Read more ...

Global Methane Emissions Soaring, But How Much Was Due to Wetlands?

Global Methane Emissions Soaring, But How Much Was Due to Wetlands?

Infographic published with permission from the authors of “Increasing anthropogenic methane emissions arise equally from agricultural and fossil fuel sources.” (Credit: Jackson... Read more ...

Computer System Assurance: A Paradigm Shift Away from Compliance to Quality

Computer System Assurance: A Paradigm Shift Away from Compliance to Quality

Our Professional Services Written by: Gary E. Ritchie, MS, Senior Validation Engineer Consultant, PSC Biotech Corporation The FDA will release the draft guidance on Computer... Read more ...

With FDA Nod, NS Pharma Duchenne Drug Becomes Sarepta Competitor

With FDA Nod, NS Pharma Duchenne Drug Becomes Sarepta Competitor

Duchenne muscular dystrophy patients whose disease is characterized by a particular genetic mutation now have a new treatment option following the FDA's Wednesday approval of a... Read more ...

Perceptive Advisors' LianBio Inks Deals With BridgeBio, MyoKardia

Perceptive Advisors' LianBio Inks Deals With BridgeBio, MyoKardia

Two California biotechs have teamed up with LianBio, a new company launched earlier this week by hedge fund Perceptive Advisors, as part of deals that expand their reach into... Read more ...

F2G Lands $60M for a New Tack on Taking Out Rare Fungal Infections

F2G Lands $60M for a New Tack on Taking Out Rare Fungal Infections

Fungal infections might not immediately come to mind as rare diseases, but growing resistance to older drugs means that patients who develop these infections have limited... Read more ...

Calliditas gets controlling stake, option to buy out Genkyotex and its...

Calliditas gets controlling stake, option to buy out Genkyotex and its failed PBC drug badams Fri, 08/14/2020 - 05:07 Read more ...

17β-Estradiol affects the innate immune response in common carp

Abstract Inflammation is the evolutionary conserved immune response to harmful stimuli such as pathogens or damaged cells. This multistep process acts by removing injurious... Read more ...

Chutes & Ladders-WuXi taps veteran operations head Dong to lead new vaccines...

Chutes & Ladders-WuXi taps veteran operations head Dong to lead new vaccines unit kblankenship Fri, 08/14/2020 - 08:23 Read more ...

Team discovers a new role for a well-known molecule as a plant hormone

Researchers at the University of Maryland have discovered an entirely new role for a well-known plant molecule called ACC, providing the first clear example of ACC acting on... Read more ...